Q3 FY2026
Filed Nov 12, 2026Electra Therapeutics reports Q3 2026 net loss of $23.9 million as R&D and G&A expenses rise following its September 2026 IPO; cash position at $402.5 million
The filing reports clinical and registrational progress and a cash position of $402.5 million, but net loss rose from $(18,092) thousand to $(23,928) thousand in the quarter and the release gives no revenue line, no prior-quarter comparison and no guidance.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total operating expenses, Q3 2026GAAP | $25,061 | – | – |
| Research and development expenses, Q3 2026GAAP | $17.27M | – | – |
| General and administrative expenses, Q3 2026GAAP | $7,793 | – | – |
| General and administrative, related party, Q3 2026GAAP | — | – | – |
| Loss from operations, Q3 2026GAAP | $(25,061) | – | – |
| Interest income, Q3 2026GAAP | $1,133 | – | – |
| Interest expense, related party, Q3 2026GAAP | — | – | – |
| Total other income (expense), net, Q3 2026GAAP | $1,133 | – | – |
| Net loss, Q3 2026GAAP | −$23.93M | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, Q3 2026GAAP | $(3.47) | – | – |
| Total operating expenses, nine months 2026GAAP | $75,291 | – | – |
| Research and development expenses, nine months 2026GAAP | $58,905 | – | – |
| General and administrative expenses, nine months 2026GAAP | $16,386 | – | – |
| General and administrative, related party, nine months 2026GAAP | — | – | – |
| Loss from operations, nine months 2026GAAP | $(75,291) | – | – |
| Interest income, nine months 2026GAAP | $2,453 | – | – |
| Interest expense, related party, nine months 2026GAAP | — | – | – |
| Other income (expense), nine months 2026GAAP | $(2) | – | – |
| Total other income (expense), net, nine months 2026GAAP | $2,451 | – | – |
| Net loss, nine months 2026GAAP | $(72,840) | – | – |
| Deemed dividend to Series C redeemable convertible preferred stockholders, nine months 2026GAAP | $(9,675) | – | – |
| Net loss attributable to common stockholders, nine months 2026GAAP | $(82,515) | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, nine months 2026GAAP | $(35.24) | – | – |
| Cash, cash equivalents and marketable securities, as of September 30, 2026other | $402.5M | – | – |
| Total assets, as of September 30, 2026other | $410,822 | – | – |
| Total stockholders' equity, as of September 30, 2026other | $392,905 | – | – |
Capital returns
- No share repurchases or dividends are reported. The filing reports a deemed dividend of $(9,675) thousand to Series C redeemable convertible preferred stockholders for the nine months ended September 30, 2026.
What drove it
- The company's own statement attributes the expansion of its cash position to the September 2026 IPO, with $320.0 million in net proceeds included in the $402.5 million total.
- Research and development expenses were $17,268 in Q3 2026 against $14,901 in Q3 2025, and $58,905 for nine months 2026 against $33,693 for nine months 2025. The filing does not state a cause for the change.
- General and administrative expenses were $7,793 in Q3 2026 against $1,813 in Q3 2025, and $16,386 for nine months 2026 against $7,734 for nine months 2025. The filing does not state a cause for the change.
- Interest income was $1,133 in Q3 2026 against $232 in Q3 2025. The related-party interest expense line is nil in 2026 and was $(1,293) in Q3 2025.
- Clinical activity described in the release includes the Phase 2/3 SURPASS trial and the COMPASS natural history study in sHLH, a Phase 1 trial of ipsoprubart in relapsed/refractory T/NK cell malignancies, and a Phase 1 healthy volunteer trial of ELA822 initiated in September 2026.
Concerns
- Net loss increased from $(18,092) in Q3 2025 to $(23,928) in Q3 2026, and nine-month net loss attributable to common stockholders was $(82,515) after the deemed dividend.
- Total operating expenses rose from $17,022 to $25,061 year over year in Q3, and from $42,391 to $75,291 year over year for nine months.
- The release states that regulators may not accept the registrational program design, including the external control study, to support approval. This is listed among the forward-looking risks.
- The release lists delays in patient enrollment, particularly in rare diseases, as a risk. Completion of enrollment in the sHLH registrational program is expected in the second half of 2027.
- The ipsoprubart clinical data cited, including the 12 frontline patients in the Phase 1b trial and the eight sHLH patients with lymphomas, are described by the company as early and from small trials. The release states that results from early or small trials may not predict later results.
- The release provides no revenue line and no operating cash flow figure, so the net loss cannot be read against any income stream in the documents.
What to watch
- ELA822 healthy volunteer data, expected in the first half of 2027.
- Initial data from the Phase 1 trial of ipsoprubart in relapsed/refractory T/NK cell malignancies, expected in the second half of 2027.
- Completion of enrollment in the SURPASS and COMPASS sHLH registrational program, expected in the second half of 2027.
- Initiation of a first-in-disease trial of ELA822 in patients with T cell-mediated immune disorders, planned for mid-2027 subject to regulatory approval.
- ASH 2026 poster presentations on December 13, 2026, abstracts 4454 and 2965.
- Quarterly operating expense trend, given the step-up in R&D and G&A year over year.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities totaled $402.5 million as of September 30, 2026, versus $86,518 (December 31, 2025 balance sheet, table units as printed).
- The figure includes $320.0 million in net proceeds from the company's September 2026 IPO, after deducting underwriting discounts, commissions and other offering expenses paid or payable.
- Electra expects its current cash position to support planned operations into 2029.
- Working capital was $389,954 as of September 30, 2026, versus $85,760 as of December 31, 2025.
- Total liabilities were $17,917 as of September 30, 2026, versus $11,208 as of December 31, 2025.
- Convertible preferred stock was $0 as of September 30, 2026, versus $251,602 as of December 31, 2025.
- Accumulated deficit was $(245,818) as of September 30, 2026, versus $(172,978) as of December 31, 2025.
- Total stockholders' equity was $392,905 as of September 30, 2026, versus a deficit of $(163,442) as of December 31, 2025.
- The filing does not present a cash flow statement or operating or free cash flow figures.
Analysis
Electra Therapeutics reported a third quarter 2026 net loss of $(23,928) thousand, against $(18,092) thousand in the third quarter of 2025. Total operating expenses were $25,061 thousand, up from $17,022 thousand. Research and development expenses were $17,268 thousand against $14,901 thousand, and general and administrative expenses were $7,793 thousand against $1,813 thousand. The release also prints the related-party general and administrative line as nil for 2026 and $308 thousand for the 2025 quarter. The release gives no explanation for the cost increases.
For the nine months ended September 30, 2026, total operating expenses were $75,291 thousand against $42,391 thousand, and net loss attributable to common stockholders was $(82,515) thousand after a $(9,675) thousand deemed dividend to Series C redeemable convertible preferred stockholders. Basic and diluted net loss per share was $(3.47) for the quarter and $(35.24) for the nine months. The release prints a prior-year nine-month per-share figure of $(1,481.57), and the weighted-average share counts printed in the table differ sharply between the two years, which reflects the change in capital structure disclosed through the IPO and the preferred stock conversion. The release does not explain the share count movement beyond the IPO reference.
The balance sheet changed materially. Cash, cash equivalents and marketable securities were $402.5 million at September 30, 2026, against $86,518 thousand at December 31, 2025. The company states that this includes $320.0 million in net proceeds from the September 2026 IPO, and that the current cash position is expected to support planned operations into 2029. Total stockholders' equity moved from a deficit of $(163,442) thousand to $392,905 thousand, and convertible preferred stock was nil at period end against $251,602 thousand at year end. Total liabilities were $17,917 thousand.
The operating narrative centres on the SIRP platform. Ipsoprubart is in a global registrational program for secondary hemophagocytic lymphohistiocytosis, with enrollment completion expected in the second half of 2027. The release reports 100% overall survival at eight weeks and a 100% overall response rate at week four in 12 frontline patients in a Phase 1b trial. It also reports objective tumor responses in all eight sHLH patients with T- or B-cell lymphomas who had available assessments, seven with complete responses. These are small-population results that the company itself describes as early. ELA822 entered a Phase 1 healthy volunteer trial in September 2026, with data expected in the first half of 2027.
The release contains no revenue, gross margin, guidance, segment, operating cash flow or prior-quarter comparison, so this read is limited to the expense, loss, balance sheet and pipeline figures printed. The year-over-year changes in the table are not printed by the company and have been left null rather than calculated. The key figures to follow are the expense run-rate against the 2029 runway statement and the timing of the 2027 readouts.
Management, verbatim
Our recent IPO positions Electra to build on our first-mover advantage in SIRP-targeted precision immune cell depletion,
Kathy Dong, PharmD, MBA, President and Chief Executive Officer
Not in the filing
stated, not guessed- Revenue and gross margin: the filing presents no revenue or cost of sales line.
- Company guidance for revenue, operating expenses or any other metric: none is printed.
- Year-over-year and quarter-over-quarter percentage changes for all metrics: not printed.
- Prior-quarter (Q2 2026) comparatives for all metrics: not printed.
- Prior-year comparative for the deemed dividend line: not printed (no prior-year figure in the table).
- Prior-year comparative for the cash, total assets and total stockholders' equity lines: the balance sheet compares to December 31, 2025, not to a prior-year period, so these are not placed in prior_year fields.
- Operating cash flow, investing cash flow, financing cash flow and free cash flow: not presented.
- Units of the condensed statement tables: the table header does not state a unit label, so table values are copied as printed. Prose figures in millions are copied separately.
- Segment or business-line revenue breakdown: not presented.
- Share repurchases and dividends on common stock: not reported.
- Consensus estimates and share price reaction: not in the documents and not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.